Drugs / AT-777
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04309734 | Oct 2021 → Jun 2022 | chronic hepatitis C virus infection | Atea Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT-777 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04309734 ↗ |
| Action | Inhibit | “inhibitor of HCV nonstructural protein 5A (NS5A)” NCT04309734 ↗ |
| Route | Oral | “Administered orally” NCT04309734 ↗ |